RYTM today
$111.85-$0.31 (-0.28%)close Nov 12, 2026Trend
DailyUptrend (starting)
4 hourLeaning Bearish
1 hourStrong Bullish
15 minExpanding
5 minExpanding
Daily trend turns down below $85.38
Key levels
Resistance$122.20
Resistance$114.75
Support$106.57
Support$101.04
Latest news & SEC filings
DealRhythm Pharmaceuticals rises after report of another bidder
AnalystGuggenheim keeps Buy rating on Rhythm Pharmaceuticals, lifts target to $147
DealAstraZeneca makes $10 billion buyout offer for Rhythm Pharmaceuticals
DealAstraZeneca offers $10 billion to acquire Rhythm Pharmaceuticals
All RYTM news →About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company that develops melanocortin-4 receptor agonists as precision medicines for rare neuroendocrine diseases. Its lead product, IMCIVREE (setmelanotide), is approved in the United States, European Union, United Kingdom, Canada and other markets to treat severe obesity and hyperphagia caused by conditions such as Bardet-Biedl syndrome and POMC, PCSK1 or LEPR deficiency. The company also has earlier-stage oral and weekly injectable MC4R agonists in clinical development and operates in North America, Europe and Asia, serving patients, physicians and healthcare systems.
Based on the company's 10-K filed Feb 26, 2026.
Nasdaq · Healthcare
RHYTHM PHARMACEUTICALS, INC. (RYTM)
What Is the Price Target for RYTM?
SEPT Low Target
$114.00
SEPT Mid Target
$145.00
SEPT High Target
$166.00
Analyst Consensus
$145.00
Is RYTM a Buy or Sell Right Now?
Thesis
- •Revenue growing 45.8% YoY with STRONG trend — consistent growth.
- •SEC filings signal active product innovation — 2 new product/expansion keywords detected in 10-K. R&D investment stable.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for RYTM.
Start Free Trial →Is RYTM Overvalued or Undervalued?
Valuation Verdict
OVERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$109.53
17
Moat Score
NONE
5/9
Piotroski Score
16.6
Altman Z-Score
What Is Smart Money Doing with RYTM?
Insider Signal
SELLING
0 buys / 11 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Meeker David P | director officer | Buy | 50,000 | $303K | Sep 14, 2026 |
| Meeker David P | director officer | Sale | 6,439 | $655K | Sep 14, 2026 |
| Meeker David P | director officer | Sale | 30,746 | $3.1M | Sep 14, 2026 |
| Meeker David P | director officer | Sale | 8,698 | $900K | Sep 14, 2026 |
| Meeker David P | director officer | Sale | 1,817 | $190K | Sep 14, 2026 |
| Meeker David P | director officer | Sale | 2,300 | $242K | Sep 14, 2026 |
| Smith Hunter C | officer | Buy | 57,187 | $1.5M | Aug 31, 2026 |
| Smith Hunter C | officer | Sale | 23,072 | $2.4M | Aug 31, 2026 |
| Smith Hunter C | officer | Sale | 11,514 | $1.2M | Aug 31, 2026 |
| Smith Hunter C | officer | Sale | 28,188 | $3.0M | Aug 31, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →RYTM Growth Story
Revenue YoY
45.8%
3yr Revenue CAGR
100.2%
EPS Growth YoY
28.34%
FCF Growth YoY
-2.4%
Revenue Trend
STRONG
Dark Pool Trades for RYTM
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for RYTM, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 22:25:45 | $112.16 | 6,111 | $$685K | BUY |
| 21:00:16 | $112.16 | 2,156 | $$242K | BUY |
| 21:00:16 | $112.16 | 11,313 | $$1.3M | BUY |
| 20:58:29 | $112.60 | 1,375 | $$155K | SELL |
| 19:51:57 | $114.91 | 5,000 | $$575K | SELL |
5 dark pool trades shown · $$2.9M preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for RHYTHM PHARMACEUTICALS, INC. (RYTM) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →RYTM — frequently asked questions
What is RYTM stock price today?
RHYTHM PHARMACEUTICALS, INC. (RYTM) is at $111.85, down 0.28% (-$0.31) at the Nov 12, 2026 close.
Why is RYTM stock moving today?
Latest RYTM news — Nov 6, 2026: Rhythm Pharmaceuticals rises after report of another bidder · Nov 5, 2026: Guggenheim keeps Buy rating on Rhythm Pharmaceuticals, lifts target to $147
Why did RYTM stock move on Nov 3, 2026?
Rhythm Pharmaceuticals shares closed at $86.44, up 1.90% on heavy volume of over 7 million shares, after the drugmaker reported a narrower-than-expected quarterly loss and revenue that topped forecasts. The company also announced an amendment to its bivamelagon license agreement and raised $750 million in financing, a bullish development that could support future growth.
What is the RYTM price target?
The average analyst price target for RYTM is $145.00, ranging from $114 to $166, based on 11 analysts. Latest: Guggenheim maintains on Nov 5, 2026.
What do analysts rate RYTM?
Analyst ratings for RYTM: 0 Buy, 19 Hold, 0 Sell — consensus Hold.
Did RYTM beat earnings?
RYTM last reported on Nov 3, 2026: EPS -$0.61 vs -$0.71 expected — a beat of 14.0%.
Does RYTM pay a dividend?
Yes. RYTM's dividend yield is 0.08%.
What are RYTM support and resistance levels?
Support: $106.57, $101.04, $95.59. Resistance: $114.75, $122.20.
What are insiders doing with RYTM?
Insider activity: SELLING, 0 buys and 11 sells in the last 90 days.
What is the latest news on RYTM?
Nov 6, 2026: Rhythm Pharmaceuticals rises after report of another bidder · Nov 5, 2026: Guggenheim keeps Buy rating on Rhythm Pharmaceuticals, lifts target to $147 · Nov 5, 2026: AstraZeneca makes $10 billion buyout offer for Rhythm Pharmaceuticals